About the Session
Moderated by Keith Crawford, MD, PhD
Despite unprecedented advances in prostate cancer research, treatment, and precision medicine, many Black men continue to face barriers to accessing innovative therapies and participating in clinical research. Ensuring equitable access to breakthroughs requires stronger partnerships among researchers, healthcare providers, industry leaders, advocates, and the communities most affected by the disease.
Session 4 Speakers
Agenda:
Welcome and Introduction: Mr. Barney Morris, PHEN Ambassador
Moderator’s Welcome: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN
Featured Presentation: Prostate Cancer Treatment – Progress and the Next Decade of Innovation: Richard Lee, MD, PhD, Oncologist, Mass General
Fireside Chat: What Will Change Prostate Cancer Treatment? Drs. Keith Crawford and Richard Lee
Modernizing Clinical Trials and Expanding Patient Access: James Williams, Jr., Director, Federal Advocacy, American Cancer Society Cancer Action Network
Treatment Innovation Showcase: Three Approaches – One Goal
- Telix: Aimal Ahmed, MD, Senior Director, GU Oncology Medical and Scientific Affairs
- Johnson & Johnson: Fouad Moussa, PhD, Associate Director and Clinical Project Scientist; and Sarah Nagle, Senior Medical Leader
- Syncromune: Charles “Chuck” Link, MD, Executive Chairman and Chief Innovation Officer
Live Audience Q&A: Ask the Experts: What Does Innovation Mean for Patients?
Closing Remarks and Survey: Thomas Farrington, Founder and President, PHEN
PHEN In Memoriam Service: Rev. Adrian Backus, Director of Church Partnerships and Community Outreach, PHEN
THANK YOU TO OUR SPONSORS
